Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus
This is a prospective, non-interventional, open label, multi center, post marketing surveillance study designed to assess the safety, tolerability and efficacy of Linagliptin among Filipino patients with type 2 Diabetes Mellitus (DM) within the study duration of 24 weeks.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||A Post-Marketing Surveillance Study on the Safety, Tolerability and Efficacy of Linagliptin Among Filipino Patients With Type 2 Diabetes Mellitus|
- Frequency of Adverse Events and Serious Adverse Events [ Time Frame: Week 24 ] [ Designated as safety issue: Yes ]Frequency of adverse events and serious adverse events in an actual clinical setting, including hypoglycemic events.
- Change From Baseline to Week 24 of HbA1c [ Time Frame: Baseline and 24 weeks ] [ Designated as safety issue: No ]Change from baseline to week 24 of glycosylated hemoglobin (HbA1c)
- Change From Baseline to Week 24 of Fasting Blood Sugar [ Time Frame: Baseline and 24 weeks ] [ Designated as safety issue: No ]Change from baseline to week 24 of fasting blood sugar
|Study Start Date:||May 2012|
|Study Completion Date:||October 2013|
|Primary Completion Date:||October 2013 (Final data collection date for primary outcome measure)|
Please refer to this study by its ClinicalTrials.gov identifier: NCT01826370
Show 51 Study Locations
|Study Chair:||Boehringer Ingelheim||Boehringer Ingelheim|